Xinnate currently develops the first application with TCP-25 as the active pharmaceutical ingredient. The TCP-25 gel is currently in the clinical phase 1 development stage. The next step involves leveraging the TCP-25 platform to expand and develop a diverse portfolio of applications.

The overarching strategy is to advance each drug concept to a stage where a commercial deal with a larger pharmaceutical company possessing a global presence can be achieved. These transactions may involve out-licensing, partnering, licensing, strategic partnerships, joint ventures, or the sale of assets